Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP HFpEF DM

Novo Nordisk · Phase 3 · Completed · Enrollment 617

NCT04916470

EudraCT 2020-004170-22

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 2.4 mg once weekly (OW)n/rn/rn/rn/r
Semaglutide placebo OWn/rn/rn/rn/r

Not shown

  • Semaglutide 2.4 mg once weekly (OW): endpoint not reported
  • Semaglutide placebo OW: endpoint not reported